Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects

Sarah Aldred, Tommaso Sozzi, Ian Mudway, Melissa M. Grant, Hendrik Neubert, Frank J. Kelly, Helen R. Griffiths*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Plasma α-tocopherol (AT) concentrations are inversely related to cardiovascular (CV) risk; however, intervention studies with AT have failed to show any consistent benefit against CV disease (CVD). Proteomics offers the opportunity to examine novel effects of AT supplementation on protein expression and therefore improve our understanding of the physiological roles of AT. Thus, to investigate the effects of AT supplementation on the plasma proteome of healthy subjects we have undertaken a double-blind, randomised, parallel design supplementation study in which healthy subjects (n = 32; 11 male and 21 female) consumed AT supplements (134 or 268 mg/day) or placebo capsules for up to 28 days. Plasma samples were obtained before supplementation and after 14 and 28 days of supplementation for analysis of changes in the plasma proteome using 2-DE and MALDI-MS. Using semiquantitative proteomics, we observed that proapolipoprotein A1 (identified by MS and Western blotting) was altered at least two-fold. Using quantitative ELISA techniques, we confirmed a significant increase in plasma apolipoprotein A1 concentration following supplementation with AT which was both time and dose dependent (p < 0.01 after 28 days supplementation with 268 mg AT/day). These data demonstrate the time and dose sensitivity of the plasma proteome to AT supplementation. © 2006 Wiley-VCH Verlag GmbH & Co. KGaA.

Original languageEnglish
Pages (from-to)1695-1703
Number of pages9
JournalProteomics
Volume6
Issue number5
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Apolipoprotein A-I
alpha-Tocopherol
Healthy Volunteers
Protein Isoforms
Plasmas
Proteome
Proteomics
Tocopherols
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Capsules
Cardiovascular Diseases
Western Blotting
Enzyme-Linked Immunosorbent Assay
Placebos
Proteins

Keywords

  • α-Tocopherol
  • 2-DE
  • apolipoprotein A1
  • human
  • plasma proteome

Cite this

Aldred, S., Sozzi, T., Mudway, I., Grant, M. M., Neubert, H., Kelly, F. J., & Griffiths, H. R. (2006). Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects. Proteomics, 6(5), 1695-1703. https://doi.org/10.1002/pmic.200500217
Aldred, Sarah ; Sozzi, Tommaso ; Mudway, Ian ; Grant, Melissa M. ; Neubert, Hendrik ; Kelly, Frank J. ; Griffiths, Helen R. / Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects. In: Proteomics. 2006 ; Vol. 6, No. 5. pp. 1695-1703.
@article{7d27cd01e48c4c8799f816a599180664,
title = "Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects",
abstract = "Plasma α-tocopherol (AT) concentrations are inversely related to cardiovascular (CV) risk; however, intervention studies with AT have failed to show any consistent benefit against CV disease (CVD). Proteomics offers the opportunity to examine novel effects of AT supplementation on protein expression and therefore improve our understanding of the physiological roles of AT. Thus, to investigate the effects of AT supplementation on the plasma proteome of healthy subjects we have undertaken a double-blind, randomised, parallel design supplementation study in which healthy subjects (n = 32; 11 male and 21 female) consumed AT supplements (134 or 268 mg/day) or placebo capsules for up to 28 days. Plasma samples were obtained before supplementation and after 14 and 28 days of supplementation for analysis of changes in the plasma proteome using 2-DE and MALDI-MS. Using semiquantitative proteomics, we observed that proapolipoprotein A1 (identified by MS and Western blotting) was altered at least two-fold. Using quantitative ELISA techniques, we confirmed a significant increase in plasma apolipoprotein A1 concentration following supplementation with AT which was both time and dose dependent (p < 0.01 after 28 days supplementation with 268 mg AT/day). These data demonstrate the time and dose sensitivity of the plasma proteome to AT supplementation. {\circledC} 2006 Wiley-VCH Verlag GmbH & Co. KGaA.",
keywords = "α-Tocopherol, 2-DE, apolipoprotein A1, human, plasma proteome",
author = "Sarah Aldred and Tommaso Sozzi and Ian Mudway and Grant, {Melissa M.} and Hendrik Neubert and Kelly, {Frank J.} and Griffiths, {Helen R.}",
year = "2006",
month = "3",
doi = "10.1002/pmic.200500217",
language = "English",
volume = "6",
pages = "1695--1703",
journal = "Proteomics",
issn = "1615-9853",
publisher = "Wiley-VCH Verlag",
number = "5",

}

Aldred, S, Sozzi, T, Mudway, I, Grant, MM, Neubert, H, Kelly, FJ & Griffiths, HR 2006, 'Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects', Proteomics, vol. 6, no. 5, pp. 1695-1703. https://doi.org/10.1002/pmic.200500217

Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects. / Aldred, Sarah; Sozzi, Tommaso; Mudway, Ian; Grant, Melissa M.; Neubert, Hendrik; Kelly, Frank J.; Griffiths, Helen R.

In: Proteomics, Vol. 6, No. 5, 03.2006, p. 1695-1703.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects

AU - Aldred, Sarah

AU - Sozzi, Tommaso

AU - Mudway, Ian

AU - Grant, Melissa M.

AU - Neubert, Hendrik

AU - Kelly, Frank J.

AU - Griffiths, Helen R.

PY - 2006/3

Y1 - 2006/3

N2 - Plasma α-tocopherol (AT) concentrations are inversely related to cardiovascular (CV) risk; however, intervention studies with AT have failed to show any consistent benefit against CV disease (CVD). Proteomics offers the opportunity to examine novel effects of AT supplementation on protein expression and therefore improve our understanding of the physiological roles of AT. Thus, to investigate the effects of AT supplementation on the plasma proteome of healthy subjects we have undertaken a double-blind, randomised, parallel design supplementation study in which healthy subjects (n = 32; 11 male and 21 female) consumed AT supplements (134 or 268 mg/day) or placebo capsules for up to 28 days. Plasma samples were obtained before supplementation and after 14 and 28 days of supplementation for analysis of changes in the plasma proteome using 2-DE and MALDI-MS. Using semiquantitative proteomics, we observed that proapolipoprotein A1 (identified by MS and Western blotting) was altered at least two-fold. Using quantitative ELISA techniques, we confirmed a significant increase in plasma apolipoprotein A1 concentration following supplementation with AT which was both time and dose dependent (p < 0.01 after 28 days supplementation with 268 mg AT/day). These data demonstrate the time and dose sensitivity of the plasma proteome to AT supplementation. © 2006 Wiley-VCH Verlag GmbH & Co. KGaA.

AB - Plasma α-tocopherol (AT) concentrations are inversely related to cardiovascular (CV) risk; however, intervention studies with AT have failed to show any consistent benefit against CV disease (CVD). Proteomics offers the opportunity to examine novel effects of AT supplementation on protein expression and therefore improve our understanding of the physiological roles of AT. Thus, to investigate the effects of AT supplementation on the plasma proteome of healthy subjects we have undertaken a double-blind, randomised, parallel design supplementation study in which healthy subjects (n = 32; 11 male and 21 female) consumed AT supplements (134 or 268 mg/day) or placebo capsules for up to 28 days. Plasma samples were obtained before supplementation and after 14 and 28 days of supplementation for analysis of changes in the plasma proteome using 2-DE and MALDI-MS. Using semiquantitative proteomics, we observed that proapolipoprotein A1 (identified by MS and Western blotting) was altered at least two-fold. Using quantitative ELISA techniques, we confirmed a significant increase in plasma apolipoprotein A1 concentration following supplementation with AT which was both time and dose dependent (p < 0.01 after 28 days supplementation with 268 mg AT/day). These data demonstrate the time and dose sensitivity of the plasma proteome to AT supplementation. © 2006 Wiley-VCH Verlag GmbH & Co. KGaA.

KW - α-Tocopherol

KW - 2-DE

KW - apolipoprotein A1

KW - human

KW - plasma proteome

UR - http://www.scopus.com/inward/record.url?scp=33645071556&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/doi/10.1002/pmic.200500217/abstract

U2 - 10.1002/pmic.200500217

DO - 10.1002/pmic.200500217

M3 - Article

C2 - 16429457

VL - 6

SP - 1695

EP - 1703

JO - Proteomics

JF - Proteomics

SN - 1615-9853

IS - 5

ER -